Pharmacokinetics And Safety Of Ct-P17, A Proposed High Concentration (100 Mg/Ml) Adalimumab Biosimilar, In Comparison With Eu-Approved Adalimumab And Us-Licensed Adalimumab; Results Of A Phase 1, Randomized, Double-Blind, Three-Arm, Single-Dose Study In Healthy Subjects